Phase 1 Thyroid Cancer Trial, Recruiting (NCT03647358)

Phase 1 Thyroid Cancer Trial, Recruiting NCT03647358 Sponsor: Memorial Sloan Kettering Cancer Center Condition: Thyroid Cancer

Printed from Voxsanity (voxsanity.com.au) — NCT03647358 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Thyroid Cancer

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

You are an adult (18 or older) who has been diagnosed with thyroid cancer, confirmed by a tissue sample test.
You have had surgery to remove your entire thyroid gland.
You have thyroid cancer that has spread (or may have spread) to other parts of the body, or you are taking part in a program to help your cancer respond better to radioiodine treatment, and you are scheduled to receive a specific hormone injection (called Thyrogen) to prepare for a dose-measurement scan — unless your doctor has determined that scan is not needed for your care.
You and your doctor are planning to use radioiodine (called I-131) as a treatment if scans show the cancer is still present and responds to it.
You have measurable signs of disease that have been recorded within the last six months using an ultrasound, MRI, PET/CT, or CT scan.

Who may not be able to join:

You are under 18 years of age.
You are currently pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

Phase 1: approximately ~10% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.

Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Ravinder Grewal, MD, Memorial Sloan Kettering Cancer Center

Phone: 212-639-2872

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT03647358

Sponsor: Memorial Sloan Kettering Cancer Center

Phase: Phase 1

Status: Recruiting

Condition: Thyroid Cancer

Trial contact: 212-639-2872

More information: https://clinicaltrials.gov/study/NCT03647358

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

You are an adult (18 or older) who has been diagnosed with thyroid cancer, confirmed by a tissue sample test.
You have had surgery to remove your entire thyroid gland.
You have thyroid cancer that has spread (or may have spread) to other parts of the body, or you are taking part in a program to help your cancer respond better to radioiodine treatment, and you are scheduled to receive a specific hormone injection (called Thyrogen) to prepare for a dose-measurement scan — unless your doctor has determined that scan is not needed for your care.
You and your doctor are planning to use radioiodine (called I-131) as a treatment if scans show the cancer is still present and responds to it.
You have measurable signs of disease that have been recorded within the last six months using an ultrasound, MRI, PET/CT, or CT scan.

Who may not be able to join:

You are under 18 years of age.
You are currently pregnant.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Phase 1

Sponsor

Memorial Sloan Kettering Cancer Center

Registry

ClinicalTrials.gov

Start date

21 August 2018

Est. completion

1 August 2027

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

number of individual lesions response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov